Detailed analysis of the drug ingredients of Enasidenib

Enasidenib is an oral small molecule drug that acts as an isocitrate dehydrogenase type 2 (IDH2) inhibitor and is mainly used to treat patients with acute myeloid leukemia (AML) with IDH2 mutations. The pharmaceutical ingredients of ensidipine have unique characteristics in molecular structure and mechanism of action, which make it play an important role in the treatment of AML.

Ensidipine's main pharmacological effect is through inhibitingIDH2, an enzyme that normally aids cell metabolism. IDH2 mutations are common in a variety of cancers, particularly in patients with acute myeloid leukemia (AML). When the IDH2 gene is mutated, it will lead to abnormal activity of the IDH2 enzyme, thereby promoting the growth and spread of cancer cells. Ensidipine binds to the mutated IDH2 enzyme and inhibits its activity, thereby restoring normal cell metabolism and reducing the growth of cancer cells.

Specifically,IDH2 mutations cause the metabolite isocitrate (isocitrate) to be converted into 2-hydroxyglutarate (2-HG), which affects normal gene expression and cell differentiation. Ensidipine inhibits the IDH2 enzyme and reduces the production of 2-HG, thereby reversing this metabolic abnormality and helping cancer cells restore normal proliferation and differentiation.

In terms of drug preparation, ensidipine usually exists in the form of oral tablets. The dosage of the drug is 100 mg. Patients usually take it once a day under the guidance of a doctor. Ensidipine is well absorbed orally, has high bioavailability in the body, and can effectively exert its inhibitory effect.

The pharmacokinetic characteristics of ensidipine are also the basis for its therapeutic effect. It is rapidly absorbed in the body, highly bound to plasma proteins, and has a relatively long half-life. This enables it to maintain a relatively stable drug concentration during the treatment process and improve the therapeutic effect. In addition, ensidipine is metabolized in the liver through the CYP3A4 enzyme, and part of the drug ingredients are excreted in the urine.

Reference materials:https://www.idhifa.com/